DEPLOYDatabase

Robot model

V1

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot…

Track V1
Manufacturer
Vicarious Surgical
Form factor
surgical
Maturity
research
Lifecycle
active

Overview

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.

Verified vs. claimed

Maturity stage
research(Lab-stage only; no commercial or public deployment reported.)
Verified deployments
None on file
Sources on file
6 sources, view all

No verified deployments on file. DEPLOY tracks independently-sourced deployment evidence separately from manufacturer capability claims.

Key facts

Autonomy level

teleoperated by design

Maturity

research

Cash and short-term investments

$3.682 million as of March 31, 2026

Runway

through Q2 2026

Q1 2026 net loss

$7.329 million

Accumulated deficit

$253.446 million

Revenue

zero (never commercialized)

FDA clearance

none

FDA submission

none yet

Specs

Dof

9

Notes

Verified: Vicarious Surgical (Waltham MA area; went public via SPAC 2021, NYSE: RBOT) is developing the V1 single-port robot. The differentiators (9-DoF human-like instrument, immersive interface) are engineering concepts in animal-lab / design-freeze stage., Current status: DISTRESSED (the headline): Q1 2026 10-Q carries an EXPLICIT going-concern substantial-doubt. Cash + short-term investments = $3.682M (3/31/2026); runway only through Q2 2026. Q1 2026 net loss $7.329M; ZERO revenue ever (never commercialized). NYSE trading suspended Mar 3 2026, delisting commenced; moved to OTCQB Mar 24 2026. A reverse split was used as a survival maneuver., Maturity = research (gating not even submitted): NO FDA clearance and NO FDA submission yet (planned De Novo, first-in-human repeatedly delayed). V1 does nothing commercial: no revenue, no installed base, no cleared device. NO clearance = research-tier. At material risk of becoming discontinued within the runway window. RE-VERIFY within weeks given the Q2-2026 cash cliff., Claimed but NOT verified: Any completed first-in-human procedure; a firm/met FDA submission date; that the company remains a going concern past Q2 2026; successful Nasdaq relisting; AI-assist or autonomy (none cleared or commercial; teleoperated by design)., Re-verify 2026-06-03: Distress intact (Q1 2026 10-Q, filed Apr 30 2026: cash + ST investments $3.682M at 3/31/2026, runway through Q2 2026, Q1 net loss $7.329M, accumulated deficit $253.446M, still zero revenue, still NO FDA submission / NO first-in-human). NEW defensive action: applied to UPLIST to the Nasdaq Capital Market + filed a preliminary proxy for a board-authorized reverse stock split (ratio TBD) - both INTENTIONS/applications, NOT completed (does not yet meet Nasdaq initial-listing requirements). No bankruptcy, acquisition, or new financing closed. No lifecycle change; maturity stays research.

Console

immersive virtual-reality-style surgeon interface

Products

V1: single-port system with a '9-DoF human-like' instrument and an immersive VR-style surgeon interface ('transport the surgeon inside the patient'). Pre-commercial; no FDA submission yet.

Form Factor

surgical (single-port surgical robot concept: 9-DoF human-like instrument + immersive VR-style surgeon interface)

Fda clearance

none

Visualization

virtual-reality-style

Data & sources

Company filings

2

Press releases

1

News coverage

1

Web sources

2

6 sources backing this record.View all →

Pricing

No verified price is on record for V1. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

V1 on the deployment map

Where V1 is verified operating. Explore the deployment map by place and type.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Manufacturer-attributed media (1)

Manufacturer-supplied media at the model level. Not tied to an independently verified named-site deployment. Verification posture is product-showcase from the maker, distinct from the deployment-verified evidence in the section above.

PRIMARY SOURCE
Courtesy of Vicarious Surgical

Vicarious Surgical's film for its single-port V1 system with articulating 'human-like' instruments (the maker's framing). A surgeon-teleoperated system, not autonomous.

Safety record

No incidents on record for V1.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (6)

  1. https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting
  2. https://www.therobotreport.com/vicarious-surgical-faces-nyse-delisting-again/
  3. https://www.massdevice.com/vicarious-surgical-timeline-delay/
  4. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=RBOT
  5. https://www.sec.gov/Archives/edgar/data/0001812173/000121390026049749/ea0287711-10q_vicarious.htm
  6. https://www.businesswire.com/news/home/20260316676583/en/Vicarious-Surgical-Announces-Strategic-Plan-to-Pursue-Nasdaq-Listing

Common questions

What is V1?
Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.
How much does V1 cost?
V1's price is not publicly disclosed. DEPLOY has no verified price on record for V1 from Vicarious Surgical. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is V1 actually deployed in the real world?
V1 is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.
Who makes V1?
V1 is made by Vicarious Surgical, based in Waltham, Massachusetts, USA, founded in 2014.
Can you buy V1?
V1 is at research stage and is not yet available for sale.
Methodology: Verified · 6 sources (3 primary) · last reviewed 2026-07-12

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-07-12

Maturity + lifecycle

Maturity stage: research

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

2
unclassified
Unclassified source
2
primary-sec-filing
SEC filing
1
primary-company-ir
Company IR disclosure
1
secondary-trade-publication
Trade publication

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for V1.

Recent coverage

V1 in third-party press

Tesla starts FSD v14 ‘Lite’ rollout to HW3 cars

Jun 29, 2026

Q1 2026 Portfolio in Review

Apr 2, 2026

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026